Company news
Yabao Pharmaceutical Group Co. Ltd. Class A (SSE:600351) news
Yabao Pharmaceutical Group Co. Ltd. Class A news releases on 6ix. Latest, Mar 4, 2025: Announcement on Implementation Results of Share Repurchase and Share…
Press releases — page 2
Announcement on Implementation Results of Share Repurchase and Share Changes
March 3, 2025
Announcement on ZY-A001 Obtaining Notice of Approval for Drug Clinical Trials
February 14, 2025
Announcement on the Repurchased Company Shares Reaching 1% and Repurchase Progress
February 5, 2025
Announcement on the Termination of the Technology Transfer Agreement for the Traditional Chinese Medicine New Drug Project
January 17, 2025
Announcement on a Wholly-owned Subsidiary Obtaining One Drug Registration Certificate
November 21, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 4, 2024
Announcement on Correction of Report for Q3 2024
October 25, 2024
Report for Q3 2024
October 24, 2024
Announcement on Obtaining Approval of Phase II Clinical Trial for New Indication of Project SY-009
September 29, 2024
Announcement on Notice to Creditors
September 3, 2024
Announcement on Convening 2024 Semi-annual Performance Briefing
August 16, 2024
Announcement on Resolutions of the 6th Meeting of the 9th Board of Directors
August 14, 2024